KOMZIFTI® (ziftomenib), FDA-Approved for Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for Komzifti, an oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia.